問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Ophthalmology

Division of Endocrinology

Division of Ophthalmology

更新時間：2023-09-19

楊中美YANG, CHUNG-MAY
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

5Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊中美

List

14Cases

2018-11-01 - 2023-12-31

Phase III

Completed
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)

  • Condition/Disease

    Diabetic Macular Edema

  • Test Drug

    FARICIMAB (RO6867461)

Participate Sites
3Sites

Terminated3Sites

2019-03-01 - 2023-12-31

Phase III

Completed
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)

  • Condition/Disease

    nAMD

  • Test Drug

    Faricimab (RO6867461) Eylea

Participate Sites
4Sites

Terminated4Sites

2020-09-01 - 2024-10-09

Phase III

Completed
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion

  • Condition/Disease

    Macular Edema Secondary to Branch Retinal Vein Occlusion

  • Test Drug

    FARICIMAB (RO6867461)

Participate Sites
4Sites

Not yet recruiting4Sites

2020-12-01 - 2024-06-30

Phase III

Completed
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA

  • Condition/Disease

    Diabetic Macular Edema

  • Test Drug

    FARICIMAB (RO6867461)

Participate Sites
3Sites

Recruiting3Sites

2008-11-03 - 2011-01-24

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2023-04-22 - 2026-10-30

Phase III

Active
PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)

  • Condition/Disease

    Geographic Atrophy

  • Test Drug

    錠劑

Participate Sites
4Sites

Recruiting4Sites

2009-01-01 - 2010-06-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2020-08-20 - 2024-08-07

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2023-12-01 - 2032-12-31

Phase IV

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2013-08-01 - 2015-05-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB